Discover how Regeneron (NASDAQ: REGN) harmonizes biology and technology to create life-changing medicines. Join our team and explore clinical trials.

Regeneron has developed aflibercept, a VEGF inhibitor, and rilonacept, an interleukin-1 blocker. VEGF is a protein that normally stimulates the growth of blood vessels, and interleukin-1 is a …

4 days ago · Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Learn more …

Regeneron is a leading science and technology company dedicated to inventing, developing and commercializing life-transforming treatments for serious diseases.

Search for a Regeneron clinical trial based on condition, keyword, and location. Explore comprehensive information on our highlighted trials to learn more.

1 day ago · Regeneron swooped in to save the struggling 23andMe last month, bidding $256 million to acquire the genetic testing company in a bankruptcy auction. Aside from the testing …

Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, …

Jun 2, 2025 · When Regeneron's co-Founder, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the …

May 17, 2024 · Regeneron and Society for Science are pleased to present an award of $75,000 to the top First Place project. The George D. Yancopoulos Innovator Award recognizes the best …

Jun 2, 2025 · New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China. Phase 2 …